Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antibody Fragments Market

Antibody Fragments Market Share

Report ID: GMI11679
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Antibody Fragments Market Share

The market is concentrated and characterized by intense competition, with major global companies vying for market leadership. Key strategies for maintaining a competitive edge include investments in R&D and the constant launch of innovative technologies and advanced therapies. Strategic partnerships, acquisitions, and mergers are also crucial for consolidating market positions and expanding international reach. Smaller players focus on specific niches, targeting underserved areas or therapeutic applications to create competitive pressure on established players.

Antibody Fragments Market Companies

Some of the eminent market participants operating in the antibody fragments industry include:

AbbVie Inc.
Amgen
AstraZeneca
BioNTech
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc.
Johnson & Johnson
Merck & Co.
MorphoSys
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Company Limited
UCB Pharma

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In 2023, the market was valued at approximately USD 7.3 billion. Projections indicate a growth rate of 5.6% CAGR from 2024 to 2032.

The monoclonal antibody segment is forecasted to reach USD 7.5 billion by 2032. This dominance is due to the high specificity of monoclonal antibody fragments, which allows precise binding to specific antigens or receptors on diseased cells. This precision makes them highly effective in targeted therapies, particularly in oncology and autoimmune diseases.

The U.S. market is projected to reach USD 4 billion by 2032. The region has one of the highest cancer prevalence rates globally, with about 1.9 million new cancer cases diagnosed in 2022, driving the demand for cancer therapies and, consequently, antibody fragments.

Key players in the industry include AbbVie Inc., Amgen, AstraZeneca, BioNTech, Bristol